Basu Ananda, Slama Michael Q, Nicholson Wayne T, Langman Loralie, Peyser Thomas, Carter Rickey, Basu Rita
1 Endocrine Research Unit, Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, MN, USA.
2 Department of Anesthesiology, Mayo Clinic, Rochester, MN, USA.
J Diabetes Sci Technol. 2017 Sep;11(5):936-941. doi: 10.1177/1932296817697329. Epub 2017 Mar 23.
Reliability of continuous glucose monitors (CGM) is a prerequisite for therapeutic dosing of insulin without the need for confirmatory blood glucose meter measurements. Interference of CGMs with commonly prescribed substances has not been extensively evaluated.
We sought to undertake a novel pilot study to determine the susceptibility of FDA-approved CGM systems (Medtronic Guardian Sof-Sensor, Dexcom G4 Platinum) to erroneous readings in the presence of common medications. CGMs were placed on the abdomen of healthy subjects 48 hours prior to study. Subjects were admitted to the Clinical Research Trials Unit (CRTU) on the evening before study and fed a standard supper. The following morning, an oral medication was administered in the fasted state and blood was sampled for 9 hours. CGM values were compared to ambient glucose (measured with YSI) to observe variations in CGM readings. Microdialysis catheters were also placed in the abdomen to sample interstitial fluid (ISF) for drug concentrations.
Nineteen healthy drug-naïve subjects without diabetes participated in the study. A drug/substance was tested up to a maximum of nine times on separate occasions. Comparison of CGM glucose patterns to actual plasma glucose concentrations show several drugs, including lisinopril, albuterol, and acetaminophen, appear to interfere with commonly used CGM devices. Wine also interfered with CGM readings.
We conclude there is some evidence of CGM interference with lisinopril, albuterol, acetaminophen, atenolol, and red wine. Future studies are required to address interference with newer sensors being approved or in the process of approval.
连续血糖监测仪(CGM)的可靠性是在无需用血糖仪测量进行确认的情况下进行胰岛素治疗给药的前提条件。CGM对常用药物的干扰尚未得到广泛评估。
我们试图开展一项新的试点研究,以确定美国食品药品监督管理局(FDA)批准的CGM系统(美敦力监护仪软传感器、德康G4铂金版)在存在常用药物时出现错误读数的易感性。在研究前48小时,将CGM放置在健康受试者的腹部。受试者在研究前一晚入住临床研究试验单元(CRTU),并进食标准晚餐。第二天早上,在空腹状态下给予口服药物,并采集9小时的血液样本。将CGM值与环境葡萄糖(用YSI测量)进行比较,以观察CGM读数的变化。还在腹部放置了微透析导管,以采集间质液(ISF)用于药物浓度检测。
19名无糖尿病史的健康受试者参与了该研究。一种药物/物质在不同场合最多测试9次。将CGM血糖模式与实际血浆葡萄糖浓度进行比较,结果显示包括赖诺普利、沙丁胺醇和对乙酰氨基酚在内的几种药物似乎会干扰常用的CGM设备。葡萄酒也会干扰CGM读数。
我们得出结论,有一些证据表明CGM会受到赖诺普利、沙丁胺醇、对乙酰氨基酚、阿替洛尔和红酒的干扰。需要进一步的研究来解决对正在批准或正在审批过程中的新型传感器的干扰问题。